medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 3

<< Back Next >>

Ann Hepatol 2015; 14 (3)

Obeticholic acid: expanding the therapeutic landscape of NASH

Arrese M, Cabrera D, Barrera F

Language: English
References: 19
Page: 430-432
PDF size: 66.61 Kb.


Text Extraction

Currently treatment options for Non-Alcoholic Steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease (NAFLD) and one of the commonest causes of cirrhosis worldwide, are mainly limited to promotion of life style changes in diet and exercise habits as well as to control of comorbidities such as type 2 diabetes mellitus and dyslipidemia.


REFERENCES

  1. Pearlman M, Loomba R. State of the art: treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2014; 30: 223-37.

  2. Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39: 3-14.

  3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.

  4. Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009; 51: 380-8.

  5. Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009; 328: 116-22.

  6. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-8.

  7. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.

  8. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731-44.

  9. Arrese M, Karpen SJ. New horizons in the regulation of bile acid and lipid homeostasis: critical role of the nuclear receptor FXR as an intracellular bile acid sensor. Gut 2001; 49: 465-6.

  10. Arrese M, Karpen SJ. Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther 2010; 87: 473-8.

  11. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013; 86: 1517-24.

  12. Carr RM, Reid AE. FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease. Curr Atheroscler Rep 2015; 17: 500.

  13. Liu WY, Xie DM, Zhu GQ, Huang GQ, Lin YQ, Wang LR, Shi KQ, et al. Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. Expert Opin Ther Targets 2014 Dec 30:1-11. (doi:10.1517/ 14728222.2014.997711) [Epub ahead of print].

  14. Roda A, Pellicciari R, Gioiello A, Neri F, Camborata C, Passeri D, De Franco F, et al. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat. J Pharmacol Exp Ther 2014; 350: 56-68.

  15. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17: 988-97.

  16. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2014 Nov 7. pii: S0140-6736(14)61933-4. doi: 10.1016/ S0140-6736(14)61933-4. [Epub ahead of print].

  17. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, et al. Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology 2014 Dec 11. pii: S0016-5085(14)01530-3. doi: 10.1053/ j.gastro.2014.12.005. [Epub ahead of print].

  18. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology 2010; 51: 373-5.

  19. Ratziu V. Starting the battle to control non-alcoholic steatohepatitis. Lancet 2014 Nov 7. pii: S0140- 6736(14)62010-9. doi: 10.1016/S0140-6736(14)62010-9. [Epub ahead of print].




2020     |     www.medigraphic.com